ASCO 2022 | Assessing EFGR TKIs in patients with wild-type EFGR NSCLC

Joshua K. Sabari, MD, NYU Langone Health, New York, NY, comments on the use of EFGR tyrosine kinase inhibitors (TKIs) in patients with wild-type EFGR non-small cell lung cancer (NSCLC). Whilst TKIs are usually administered in patients with exon 19, 20, or 21 mutations, these class of drugs have variable efficacy in patients with wild-type EFGR NSCLC. However, antibody-drug conjugates targeting EFGR may be a promising therapeutic option for these group of patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.